Uncategorized

As the November 5 deadline approaches for state submissions to the highly anticipated $50 billion Rural Health Transformation Program (RHTP), uncertainty remains about whether – or even how – these funds will reach hospitals [CYH,…

The top story in Washington this week remains the government shutdown, but a potential meeting between Secretary of State Marco Rubio and Russian Foreign Affairs Minister Sergei Lavrov in talks to try and end the…

Even amid a government shutdown – and in some ways because of it – 4Q25 promises a large number of policy catalysts across the medtech, diagnostics, life science tools (LST), and biopharma landscapes, informing company…

The Trump administration’s new guidance on employer-sponsored fertility benefits and deal with Merck KGaA’s (MRK.GY) EMD Serono to sell select fertility drugs at most-favored-nation (MFN) prices, which were announced Thursday, boosts visibility for companies like…

We have the following thoughts about various updates on the trade front: We continue to believe that the recent trade / tariff tit for tat by China and the U.S. is mostly posturing. We see…

Policy headwinds facing pharmacy benefit managers (PBMs) [CVS, CI, UNH, ELV] remain entrenched despite shifting details since this spring. Recent developments, like California’s PBM law, White House drug pricing efforts, and the FTC litigation, underscore…

We remain cautiously optimistic that any eventual longer-term FY26 funding bill will include legislation allowing – but not requiring – Medicare coverage of multi-cancer early detection (MCED) screening [GH, EXAS, GRAL]. Larger firms may nevertheless…

We think this morning’s court ruling against Humana (HUM) in its Medicare Advantage (MA) Stars litigation is likely the end of the road in its efforts to secure a higher score for its 2026 payment…

We expect both the continued government shutdown and the U.S./China trade flare up that began on Friday to dominate Washington’s attention this week. Keep in mind, the Senate is in session this week, starting on…

Despite the nearly ubiquitous opposition of stakeholders, we think CMS will likely finalize its intention to include continuous glucose monitors (CGMs) [DXCM, ABT] in the next round of the Competitive Bidding Program (CBP), along with…